Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Filter results: >>>>
Cell Clinical Subtype Transcriptional Subtype Small Molecule Antibody Perturbagen Target Perturbagen Class Biological Replicate ID Conc Unit GR50 GEC50 GRmax GRinf GR Hill Coefficient GR_AOC GR r2 Nominal Division Rate
LY2
HR+
Luminal
LBH589
HDAC
HDAC
12319.167
uM
0.02773
0.12090
-0.9159 -1.0000 0.7461 0.8921
0.9764
1.2676
LY2
HR+
Luminal
Lestaurtinib
FLT3/JAK2/TrkA
RTK
12319.167
uM
0.15825
0.47441
-0.9708 -1.0000 1.0006 0.7010
0.9853
1.2676
LY2
HR+
Luminal
Mebendazole
12627.174
uM
0.50329
0.43275
0.0237 0.1162 1.7513 0.3409
0.9831
1.3419
LY2
HR+
Luminal
Methotrexate
DHFR
Metabolism
7477.084
uM
inf
inf
0.4295 0.4295 0.0000 0.3986
0.4934
0.9476
LY2
HR+
Luminal
Methylglyoxal
13639.184
uM
inf
inf
-0.8274 -0.8274 0.0000 0.3747
0.4895
1.5976
LY2
HR+
Luminal
MG-132
Proteasome
Proteasome
14134.189
uM
inf
inf
-0.3706 -0.3706 0.0000 0.2938
0.5072
2.7572
LY2
HR+
Luminal
MG-132
Proteasome
Proteasome
14134.189
uM
inf
inf
-0.3706 -0.3706 0.0000 0.2938
0.5072
2.7572
LY2
HR+
Luminal
MG-132
Proteasome
Proteasome
12319.17
uM
0.22251
0.27719
-0.9999 -1.0000 5.0000 0.9111
0.9545
0.4684
LY2
HR+
Luminal
MG-132
Proteasome
Proteasome
12319.17
uM
0.22251
0.27719
-0.9999 -1.0000 5.0000 0.9111
0.9545
0.4684
LY2
HR+
Luminal
MG-132
Proteasome
Proteasome
10816.145
uM
0.22071
0.27486
-0.9983 -0.9977 5.0000 0.8771
0.9969
0.7766
LY2
HR+
Luminal
MG-132
Proteasome
Proteasome
10816.145
uM
0.22071
0.27486
-0.9983 -0.9977 5.0000 0.8771
0.9969
0.7766
LY2
HR+
Luminal
Pevonedistat
NAE1
NAE1
12319.135
uM
0.08180
0.10116
-0.9468 -0.9099 4.8799 0.9801
0.9968
0.3806
LY2
HR+
Luminal
Pevonedistat
NAE1
NAE1
10816.148
uM
0.16358
0.24353
-0.7404 -0.7173 2.2359 0.7251
0.9980
0.7402
LY2
HR+
Luminal
Nelfinavir
12627.174
uM
8.39840
12.76790
-0.8520 -1.0000 2.6227 0.1651
0.9984
1.3419
LY2
HR+
Luminal
Nilotinib
ABL
nRTK
10816.145
uM
inf
inf
1.0500 1.0500 0.0000 -0.0123
-0.0004
0.7766
LY2
HR+
Luminal
Nilotinib
ABL
nRTK
12319.17
uM
inf
inf
0.9335 0.9335 0.0000 0.1304
0.1701
0.4684
LY2
HR+
Luminal
NSC 663284
CDC25
CDC
10816.152
uM
0.48617
1.24280
-0.9738 -1.0000 1.1706 0.8282
0.9683
1.0111
LY2
HR+
Luminal
NU6102
CDK1/2
CDK
12319.147
uM
18.25020
28.30340
-0.7907 -0.9998 2.5033 0.2886
0.8469
1.1783
LY2
HR+
Luminal
NU6102
CDK1/2
CDK
10816.147
uM
31.85780
39.68620
-0.8650 -1.0000 5.0000 0.1140
0.9659
0.7283
LY2
HR+
Luminal
Nutlin 3a
MDM2
MDM2
7477.066
uM
5.95670
7.42050
-1.0000 -1.0000 5.0000 0.4047
0.9709
0.3409
LY2
HR+
Luminal
Nutlin 3a
MDM2
MDM2
10380.066
uM
5.08760
12.14760
-0.8275 -1.0000 1.2623 0.2564
0.9954
1.2245
LY2
HR+
Luminal
Olomoucine II
CDK1
CDK
12319.147
uM
2.25940
5.91090
-0.9046 -1.0000 1.1424 0.6134
0.9123
1.1783
LY2
HR+
Luminal
Olomoucine II
CDK1
CDK
10816.147
uM
5.0970
6.34790
-0.9997 -0.9981 5.0000 0.4155
0.9979
0.7283
LY2
HR+
Luminal
Omipalisib
PI3K
PI3K
10380.087
uM
0.0120
0.02509
-0.7779 -0.7670 1.2601 0.9793
0.9962
1.3481
LY2
HR+
Luminal
Oxaliplatin
DNA cross-linker
DNA cross-linker
9536.011
uM
7.84540
27.8330
-0.9125 -1.0000 0.8676 0.5254
0.9629
1.2640